SRR26320080
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- KRAS_SIGNALING_DN+0.420
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.390
- PANCREAS_BETA_CELLS+0.380
- MYOGENESIS+0.370
- ANGIOGENESIS+0.300
- COAGULATION+0.280
- SPERMATOGENESIS+0.220
- APICAL_SURFACE+0.200
- TNFA_SIGNALING_VIA_NFKB+0.190
- ESTROGEN_RESPONSE_LATE+0.130
Top 10 suppressed
- PROTEIN_SECRETION-0.610
- INTERFERON_ALPHA_RESPONSE-0.560
- OXIDATIVE_PHOSPHORYLATION-0.550
- MYC_TARGETS_V1-0.500
- PI3K_AKT_MTOR_SIGNALING-0.450
- DNA_REPAIR-0.440
- UNFOLDED_PROTEIN_RESPONSE-0.440
- INTERFERON_GAMMA_RESPONSE-0.370
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.360
- MITOTIC_SPINDLE-0.340
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
5 twins match this tumor's tissue · 5 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR1458810 | GTEX | — | 0.903 |
| 2 | SRR1083100 | GTEX | — | 0.901 |
| 3 | MNG204 | — | — | 0.899 |
| 4 | TCGA-ZF-A9R0-01A-11R-A38B-07 | — | — | 0.897 |
| 5 | SRR4296064 | — | cohortA1 | 0.897 |
| 6 | SRR1340301 | GTEX | — | 0.897 |
| 7 | SRR1516036 | — | — | 0.896 |
| 8 | SRR1079281 | GTEX | — | 0.895 |
| 9 | SRR1361674 | GTEX | — | 0.890 |
| 10 | TCGA-FJ-A3Z7-01A-12R-A23N-07 | — | — | 0.890 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 17 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| KRAS_SIGNALING_DN | 0.420 | Remibrutinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.390 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.380 | Cobimetinib | — uncovered |
| MYOGENESIS | 0.370 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.300 | Remibrutinib | — uncovered |
| COAGULATION | 0.280 | Binimetinib | — uncovered |
| SPERMATOGENESIS | 0.220 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.200 | Temsirolimus | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.190 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.130 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.090 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.090 | Inavolisib | — uncovered |
| HYPOXIA | 0.070 | Idelalisib | — uncovered |
| APICAL_JUNCTION | 0.050 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.050 | Remibrutinib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.050 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.030 | Inavolisib | — uncovered |